AmirAli Talasaz is the co-CEO of the leading precision oncology company, Guardant Health, Inc, which he co-founded in 2012 with Dr. Helmy Eltoukhy. Prior to co-founding Guardant Health, he was senior director of Diagnostics Research at Illumina and led the efforts for emerging clinical applications of next-generation genomic analysis. During that time, he developed different genomic technologies suitable for clinical applications. Before Illumina, he founded Auriphex Biosciences, which focused on purification and genetic analysis of circulating tumor cells for cancer management, which was later acquired by Illumina in 2009. Talasaz received his PhD in electrical engineering and MSc in management science from Stanford University, where he led the Technology Development Group at Stanford Genome Technology Center.